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Tyrosyl-DNA phosphodiesterase 2 (TDP2) is a 5′-tyrosyl
DNA phosphodiesterase important for the repair of DNA
adducts generated by non-productive (abortive) activity of
topoisomerase II (TOP2). TDP2 facilitates therapeutic resistance
to topoisomerase poisons, which are widely used in the treatment
of a range of cancer types. Consequently, TDP2 is an interesting
target for the development of small molecule inhibitors that
could restore sensitivity to topoisomerase-directed therapies.
Previous studies identified a class of deazaflavin-based molecules
that showed inhibitory activity against TDP2 at therapeutically
useful concentrations, but their mode of action was uncertain.
We have confirmed that the deazaflavin series inhibits TDP2
enzyme activity in a fluorescence-based assay, suitable for
high-throughput screen (HTS)-screening. We have gone on to
determine crystal structures of these compounds bound to a
‘humanized’ form of murine TDP2. The structures reveal their
novel mode of action as competitive ligands for the binding site
of an incoming DNA substrate, and point the way to generating
novel and potent inhibitors of TDP2.
Key words: deoxyribonucleic acid (DNA) synthesis and repair,
drug discovery and design, topoisomerases.
INTRODUCTION
Tyrosyl-DNA phosphodiesterase 2 (TDP2) {also known as
TRAF and TNF receptor-associated gene (TTRAP) [1] or
ETS1-associated protein II (EAPII) [2]} is a 5′-tyrosyl DNA
phosphodiesterase that can remove the covalently-attached
abortive complexes generated by DNA topoisomerase II (TOP2)
when it is unable to complete its normal catalytic cycle [3,4].
TDP2 has also been co-opted by picornaviruses as the ‘unlinkase’
that releases nascent RNA from its VPg protein primer during
viral replication [5].
TOP2 generates transient double-strand breaks (DSBs) in
genomic DNA that relieve torsional stress introduced during
transcription and replication [6]. The mechanism of DNA strand
cleavage by TOP2 involves formation of a covalent reaction
intermediate between the side chain of a catalytic tyrosine in
the enzyme, and the 5′-phosphate at the site of the DNA-strand
break. TOP2 functions as a dimer, and produces a staggered DSB,
with the nicks in the two strands separated by 4 bp. Normally,
following passage of a distal segment of duplex DNA through
the break, TOP2 facilitates attack on the phosphotyrosyl bonds
by the free 3′-OH at the nicks, resealing the break and releasing
the enzyme. In some circumstances, TOP2 is unable to complete
the reaction cycle, leaving it covalently attached to the DSB 5′-
termini in a highly toxic, abortive, ‘cleavage complex’ that can
severely disrupt replication and transcription. Fortunately, this
type of DNA lesion is efficiently repaired, in part though the
action of TDP2, which hydrolyses the phosphotyrosyl bond in
a magnesium cofactor-dependent reaction, leaving ligatable 5′-
phosphate moieties.
TOP2 ‘poisons’ such as doxorubicin (Adriamycin) are known to
intercalate into DNA (PDB: 1D12; [7]); amsacrine (mAMSA) and
etoposide (VP-1) have also been demonstrated to bind selectively
at the nick sites of a TOP2–DNA complex (PDB: 4G0U, 3QX3;
[8]) and prevent resealing of the strands. These interactions
promote the cumulative formation of abortive TOP2–DNA
complexes, leading ultimately to cell death in rapidly proliferating
cells. Consequently, TOP2 poisons are potent anticancer agents
[9], and are currently used in the clinic either as monotherapies,
or as components of combination therapies for a range of tumour
types [10–12]. However, the abortive complexes promoted by
TOP2 poisons can be rescued by the action of TDP2, so that
variations in cellular TDP2 activity (natural or tumour-specific)
can influence the clinical efficacy of these drugs, and are therefore
an important determinant of response to chemotherapy in the
individual patient and tumour. Consequently, TDP2 has attracted
interest as a target for small molecule inhibitors that might have
utility in overcoming innate or acquired resistance to TOP2
poisons.
A series of potent TDP2 inhibitors based on a deazaflavin
scaffold have previously been described, but their molecular mode
of action could not be determined and the rational exploitation of
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structure–activity relationships (SARs) was consequently limited
[13]. Using a ‘humanized’ mouse TDP2 expression construct,
we have now determined X-ray crystal structures of the catalytic
domain of TDP2 in complex with deazaflavin inhibitors, revealing
the unusual molecular interactions underpinning their mode of
action. These results provide a platform for structure-based drug
design that will greatly assist the future development of small
molecule inhibitors of human TDP2.
MATERIALS AND METHODS
Expression constructs
hTDP2CAT
DNA encoding the catalytic domain of human TDP2 (amino
acids 113–362) was cloned into pET-28a (Novagen, Merck
Chemicals). Using standard site-directed mutagenesis techniques,
a single-point mutant – C273S – was subsequently introduced
into this expression construct; improving the behaviour of the
recombinant protein, qualitatively with respect to both solubility
and aggregation.
mTDP2CAT/m2hTDP2CAT
Synthetic genes codon-optimized for Escherichia coli expression
were sub-cloned into an in-house modified form of pET-15b,
which encodes an N-terminal His-small ubiquitin-like modifier
(SUMO) affinity/solubility tag that is cleavable by sentrin-
specific protease 1 (SENP1) protease (Genscript). The mTDP2CAT
expression construct encodes amino acids Leu118–Leu370 of the
full-length gene. The m2hTDP2CAT construct encodes the same
amino acid range, but with the following series of mutations:
E242G, Q278R, Y321C and H323L.
Protein expression and purification
hTDP2CAT
Transformed colonies of E. coli strain B834 (DE3) were
used to inoculate a 250 ml flask containing 50 ml of Turbo
broth (Molecular Dimensions) supplemented with kanamycin
(50 μg/ml). The inoculated culture was grown at 37 ◦C, at 220
rpm, in an orbital shaking incubator until the absorbance at 600 nm
reached approximately 1.5. The culture was then stored overnight
at 4 ◦C.
The following day, 20 ml of the overnight culture was used
to inoculate a 2 litre flask containing 1 litre of Turbo broth
supplemented with antibiotic as before. Cultures were grown
at 37 ◦C, at 220 rpm, in an orbital shaking incubator until
the absorbance at 600 nm again reached approximately 1.5.
Recombinant protein expression was then induced by the addition
of 0.4 mM IPTG, and the culture incubated for a further 3.5 h at
a reduced temperature of 30 ◦C. Cells were then harvested by
centrifugation at 7548 g, for 10 minutes at 4◦C, and the resulting
cell pellet stored at − 80 ◦C until required.
The cell pellet arising from 4 litres of culture was resuspended
in buffer A: 50 mM HEPES/NaOH, pH 7.5, 250 mM NaCl,
10 mM imidazole, 0.5 mM TCEP, supplemented with protease
inhibitors (Roche), then disrupted by sonication, and the resulting
lysate clarified by high-speed centrifugation at 40000 g, for
60 min at 4 ◦C.
The supernatant was applied to a batch/gravity flow column
containing 10 ml of Talon resin (TaKaRa Bio) pre-equilibrated
in buffer A. After incubation (with rolling) for a period of 1 h at
4 ◦C, any unbound material was removed by sequential washes
with buffer A. Retained protein was then eluted by application of
the same buffer supplemented with 300 mM imidazole, pH 7.5.
The eluate was diluted, in order to reduce the salt concentration
to <150 mM NaCl, and then applied to a 5 ml HiTrap Heparin
HP column (GE Healthcare) equilibrated in buffer B: 50 mM
HEPES/NaOH, pH 7.5, 150 mM NaCl, 1 mM TCEP. Unbound
material was first removed by application of five column volumes
of the same buffer. Any retained protein was eluted, through
application of a linear salt gradient (0.15–1 M NaCl) to the
column.
A HiLoad 16/600 Superdex 75 pg size exclusion column (GE
Healthcare) was used to purify hTDP2-CAT to homogeneity in
20 mM HEPES/NaOH, pH 7.5, 300 mM NaCl, 0.5 mM TCEP.
mTDP2CAT/m2hTDP2CAT
A similar protocol was also used to purify both mTDP2CAT
and m2hTDP2CAT, with the following alterations: E. coli
strain: Rosetta 2(DE3)pLysS (Novagen); antibiotic selection:
50 μg/ml ampicillin/34 μg/ml chloramphenicol. The His-SUMO
affinity/solubility tag was cleaved overnight at 4 ◦C by the addition
of SENP1 protease, after the initial Talon capture step.
Thermal denaturation
For thermal denaturation, samples containing protein at 1.7 μM
and 5 x SYPRO Orange (diluted from a 5000 x stock supplied in
DMSO; Sigma–Aldrich) were prepared in sample buffer: 50 mM
HEPES/NaOH, pH 7.5, 300 mM NaCl, 0.5 mM TCEP. Either
DMSO alone or compound [dissolved in 100% (v/v) DMSO
at its maximum solubility] was then added; producing a final
concentration of 3% (v/v) DMSO. Denaturation curves were
monitored in 96-well PCR plates using a Roche LightCycler 480
II, with 465 nm and 580 nm filters for excitation and emission
wavelengths respectively. The programme was as follows: 1 min
at 20 ◦C, followed by a continuous increment of 0.03 ◦C/s to a final
temperature of 85 ◦C. Temperature midpoints (Tm) for each folded
to unfolded transition were determined by non-linear regression
fitting of a modified Boltzmann model to normalized data in Prism
6.0 (version 6.0h, GraphPad Software).
Y = (an X + bn) + (ad X + bd) − (an X + bn)
1 + e Tm−Xm
where an and ad are the slopes and bn and bd the y-intercepts, of the
native and denatured baselines respectively. Tm is the temperature
midpoint of the transition from native to denatured states and m
represents a generic slope factor.
Fluorescence-based enzyme activity assay
Substrate oligonucleotide containing a 5′-phosphotyrosine (5′-Y-
GATCTAAAAGACT-3′) conjugated to FITC was purchased from
Midland Certified Reagents.
This assay is a modified version of that reported by [14].
Briefly, enzyme assays were run in black 384-well plates, in
50 mM Tris/HCl, pH 8.0, 10 mM MgCl2, 80 mM KCl, 0.05%
(v/v) Tween-20, 1 mM DTT. Fifty picomoles of hTDP2CAT
were combined with 25 nM substrate oligonucleotide, in a final
volume of 15 μl, for a period of 10 min, before addition of
quench reagents (Gyrasol Technologies; sensor diluted 1:15 with
enhancer buffer). Fluorescence was subsequently measured in a
PHERAstar multimode plate reader (BMG Labtech GmbH) with
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an excitation wavelength of 490 nm, and an emission wavelength
of 520 nm. The built-in analysis tools of Prism 6.0 was used to
examine all experimental data.
Gel-based enzyme activity assay
This assay is a modified version of that reported by [3,4]. Briefly,
recombinant TDP2CAT proteins were diluted with reaction buffer:
50 mM Tris/HCl, pH 7.5, 50 mM KCl, 1 mM MgCl2, 1 mM
DTT to produce final concentrations of 1 nM (for hTDP2CAT
and m2hTDP2CAT) or 3 nM (for mTDP2CAT) in a volume of
16.2 μl – either in the presence or absence of compound [50 nM
for hTDP2CAT and m2hTDP2CAT, 150 nM for mTDP2CAT; 1%
(v/v) final DMSO concentration]. To start the reaction, 1.8 μl
of radiolabelled 5′-phosphotyrosyl DNA substrate was added to
the mixture, then incubated at 37 ◦C. At 2, 5 and 10 min time-
points, 6 μl of the reaction mixture was withdrawn, and stopped
by the addition of formamide loading buffer. Samples were then
analysed by denaturing PAGE, visualized by phosphorimager,
with intensities of substrate and product bands measured by
GelAnalyzer2010 software (http://www.gelanalyzer.com).
Crystallization and data collection
hTDP2CAT
Crystals of hTDP2CAT were grown at 20 ◦C in 24-well hanging-
drop vapour-diffusion plates, mixing 1 μl of protein at 7.5 mg/ml
with 1 μl of 100 mM Bis–Tris propane, pH 7.0, 0.5 M NaCl,
0.05 M magnesium acetate, 1.5% (v/v) trimethylamine N-
oxide, equilibrated against 500 μl of the same solution. Crystals
were swiped successively through buffers containing increasing
concentrations of cryo-protectant, before being plunged into
liquid nitrogen; 30% (v/v) glycerol was sufficient to prevent ice
formation.
Diffraction data to 3.1 Å (1 Å=0.1 nm) resolution were
collected at the Diamond Light Source (DLS) on beamline I04.
Crystals grew in space group P31 2 1, with two molecules of
hTDP2CAT comprising the asymmetric unit.
hTDP2CAT/163
Crystals of hTDP2CAT/163 were grown at 20 ◦C in 24-
well hanging-drop vapour-diffusion plates, mixing 1 μl of
complex (1:2.7 molar ratio protein: compound) at approximately
7.5 mg/ml, with 1 μl of 1.2 M D/L-malic acid pH 7.0, 0.1 M
Bis–Tris propane pH 7.0, 3% (v/v) DMSO, equilibrated against
500 μl of the same solution. Crystals were swiped successively
through buffers containing increasing concentrations of cryo-
protectant, before being plunged into liquid nitrogen; 40% (w/v)
sucrose was sufficient to prevent ice formation.
Diffraction data to 3.4 Å resolution were collected at the
Diamond Light Source (DLS) on beamline I04. Crystals grew
in space group P65 2 2, with a single molecule of hTDP2CAT in
complex with 163 comprising the asymmetric unit.
m2hTDP2CAT/163
Crystals of m2hTDP2CAT/163 were grown at 20 ◦C in 24-
well hanging-drop vapour-diffusion plates, mixing 1 μl of
complex (1:2.7 molar ratio protein: compound) at approximately
7.5 mg/ml, with 1 μl of 0.1 M Bis–Tris propane pH 7.5, 0.2 M
sodium citrate, 20% (w/v) PEG3350, 0.3% (v/v) DMSO,
equilibrated against 500 μl of the same solution. Crystals
were swiped successively through buffers containing increasing
concentrations of cryo-protectant, before being plunged into
liquid nitrogen; 8% (v/v) glycerol + 5% (w/v) glucose was
sufficient to prevent ice formation.
Diffraction data to 1.8 Å resolution were collected at the
Diamond Light Source (DLS) on beamline I04. Crystals grew
in space group P21, with two molecules of m2hTDP2CAT, both in
complex with 163, comprising the asymmetric unit.
m2hTDP2CAT/148
Crystals of m2hTDP2CAT/148 were grown at 20 ◦C in 24-
well hanging-drop vapour-diffusion plates, mixing 1 μl of
complex (1:2.7 molar ratio protein: compound) at approximately
7.5 mg/ml, with 1 μl of 0.1 M Bis–Tris propane pH 6.5, 0.2 M
sodium tartrate, 20% (w/v) PEG3350, 0.3% (v/v) DMSO,
equilibrated against 500 μl of the same solution. Crystals
were swiped successively through buffers containing increasing
concentrations of cryo-protectant, before being plunged into
liquid nitrogen; 8% (v/v) glycerol + 5% (w/v) glucose was
sufficient to prevent ice formation.
Diffraction data to 1.7 Å resolution were collected at the
Diamond Light Source (DLS) on beamline I04. Crystals grew
in space group P21, with two molecules of m2hTDP2CAT, both in
complex with 148, comprising the asymmetric unit.
Phasing, model building and refinement
All diffraction data were collected at 100 K. Data were integrated
using the software package XDS [15], and then processed using
the Pointless/Aimless/Ctruncate pipeline of the CCP4 software
suite [16–19]. Phases were obtained by molecular replacement,
using PHASER with 4GYZ (mTDP2-CAT) as a search model
[20]. An iterative combination of manual building in Coot [21]
and refinement with either phenix.refine [22] or BUSTER [23]
produced the final models.
Compounds
Compounds either were provided by the Cancer Research UK
Manchester Institute Drug Discovery Unit or were re-synthesized
in-house by LP or M.P., following the published protocols [13].
RESULTS
Structure of the human TDP2 catalytic domain
We obtained crystals of the catalytic domain of human TDP2
(Figure 1A; hTDP2CAT – residues 113–362), in its unliganded
form, using protein expressed in E. coli and purified using standard
chromatographic procedures (see ‘Materials and Methods’). The
expression construct contains a single-point mutant – C273S –
which removes a potentially reactive surface cysteine, and that
in our hands significantly improved the expression levels and
solubility of the recombinant protein.
The structure of hTDP2CAT was determined by molecular
replacement, with the catalytic domain of mouse TDP2 as a
search model (PDB: 4GYZ). However, crystals of hTDP2CAT
typically diffracted both poorly and anisotropically. Through
iterative screening of many crystals, we were eventually able
to collect a dataset that could be truncated isotropically to a
maximum resolution of 3.1 Å (see Table 1). The fold of the
human protein is highly similar to that of mouse [24], worm [25],
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Figure 1 Structure of the catalytic domain of human TDP2
(A) Schematic representation of human TDP2, highlighting the relative positions of its component domains; where UBA-L is Ubiquitin associated-like domain. The amino acid boundaries of the
hTDP2CAT expression construct are indicated by the dotted box. The position of the C273S mutation introduced to improve protein solubility is also indicated. (B) Superposition of TDP2 catalytic
domains. Structures for human, mouse, worm and zebrafish TDP2CAT are each shown in ribbon representation. RMSD values, over the indicated number of equivalent atom positions, were calculated
using PyMOL (www.pymol.org). (C) Stereo-view of the X-ray crystal structure of hTDP2CAT. Molecular cartoons are coloured from bluered, from the visible N- to C-terminus. The position of the
M7-loop or motif is additionally highlighted.
and zebrafish [25] (Figures 1B and 1C) but with some important
differences – see expanded description below.
Deazaflavin inhibitors of TDP2
A series of small molecule deazaflavin inhibitors of human TDP2
have previously been described [13], with examples showing
in vitro biochemical activity against the isolated enzyme in the
nanomolar concentration range (Figure 2A). However, the precise
mode of action of these compounds was unclear, and in the
absence of an experimentally determined binding site, the SARs
were difficult to rationalize.
As the original high-throughput screen (HTS) screens were
performed with full-length human TDP2, we first sought to
confirm binding of these compounds to hTDP2CAT by thermal
denaturation [26]. Using the most potent reported deazaflavin
– compound 163 [13], we observed a shift in the temperature
midpoint (Tm) of hTDP2CAT from 48.7 ◦C in the unliganded state,
to 51.5 ◦C in the presence of compound 163 at a concentration of
300 μM. These results are indicative of moderately tight binding
of 163 to hTDP2CAT (Figure 2B).
We also confirmed inhibition of catalytic activity by
three deazaflavin compounds, by using a modified form of
a fluorescence-based assay [14]. A phosphotyrosyl moiety
conjugated to FITC was readily removed from the 5′ end of a
single-stranded oligonucleotide substrate by hTDP2CAT in a dose-
dependent manner (Supplementary Figures S1A and S1B). We
could subsequently determine Km for the oligonucleotide substrate
(208 +− 23 nM), Kcat for the reaction under the experimental
conditions tested (1.58 +− 0.06 s− 1; Figure 2C), as well as IC50
values for each of the deazaflavins; 163: 19, 148: 103, 149: 489 nM
(Figure 2D). The IC50 rank order is in agreement with the previ-
ously reported EC50 values, which used full-length human TDP2
and BIOMOL Green as a detection/quantification agent [13].
Low-resolution co-crystal structure of hTDP2CAT bound to 163
As with the apo-hTDP2CAT crystals, co-crystals with 163 presented
severe problems with anisotropy during data collection. Again,
multiple crystals were screened before a dataset that could be
truncated isotropically, to a maximum resolution of 3.4 Å, was
obtained (Table 1). Despite the low-resolution, which prevents
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Figure 2 Small molecule Inhibitors of human TDP2
(A) Chemical drawings of four deazaflavin-based inhibitors of human TDP2, as described by Raoof et al. [13]. Compound numbering and EC50 values are as previously reported. (B) Thermal
denaturation profiles for hTDP2CAT in the absence or presence of 300 μM 163. The experimental data (data points coloured in black) were fitted with a modified Boltzmann model to obtain the
indicated T m for the apo- (red curve) or liganded (blue curve) forms of the protein. (C) Michaelis–Menten curve for hTDP2CAT using the fluorescence-based enzyme assay. Fifty picomoles of
hTDP2CAT were incubated with substrate oligonucleotide for a period of 10 min, before the addition of Gyrasol reagents. Experimental data were fitted with a standard Michaelis–Menten equation
(Prism 6, Graphpad software) in order to determine K m and V max parameters. Data points are the mean of three independent experiments, with error bars representing one S.D. (D) Dose–response
curves for inhibition of hTDP2CAT by increasing concentrations of the indicated deazaflavin. See associated key for details, and IC50 values determined. Data points are the mean of six replicates, with
error bars representing one S.D. (E) Molecular cartoon highlighting the binding position of 163, relative to the active site of hTDP2CAT. The compound packs against an extended hydrophobic shelf
(light grey molecular surface + stick representation) formed by the side chains of Trp297, Thr299, Leu305, Ile307, Cys311, Leu313 and Phe315. The compound binds at a distance (>9 A˚) from the active
site of the enzyme, as indicated by the side chains of Asp122 and Glu152, and the magnesium cofactor (purple sphere). (F) Top: representative image for the gel-based enzyme activity assay. hTDP2CAT
efficiently catalyses the conversion of a 5′-phosphotyrosylated (5′-Y) DNA duplex substrate to a 5′-phosphorylated product (5′-P) with time. Although 163 clearly inhibits the human enzyme, it is
ineffective against the mouse equivalent. Bottom: quantification of gel-based assay. Data represent the mean of three independent experiments, with errors bars representing one S.D.
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
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Table 1 Data collection and refinement statistics
*Values in parentheses are for highest-resolution shell. ‡Data isotropic to this resolution. §PDB entry used as ‘reference model’ during refinement.
hTDP2-CAT hTDP2-CAT + 163 m2hTDP2-CAT + 163 m2hTDP2-CAT + 148
PDB: 5J3P PDB: 5J3S PDB: 5J3Z PDB: 5J42
Data collection
Space group P3121 P6522 P21 P21
Cell dimensions
a,b,c (A˚) 92.54, 92.54, 119.07 68.52, 68.52, 209.51 61.00, 42.80, 108.75 61.05, 42.87, 109.05
α, β , γ (◦) 90, 90,120 90, 90, 120 90, 94.15, 90 90, 94.05, 90
Resolution (A˚) 47.79–3.10 (3.31–3.10)* 45.22–3.40 (3.67–3.40) 42.8–1.80 (1.84–1.80) 42.07–1.70 (1.73-1.70)
Rmerge 0.133 (0.731) 0.256 (1.876) 0.051 (0.166) 0.043 (0.810)
Rmeas 0.170 (0.932) 0.299 (2.185) 0.072 (0.233) 0.061 (1.133)
Rpim 0.103 (0.571) 0.168 (1.111) 0.050 (0.164) 0.042 (0.791)
MnI/ σ I 9.6 (1.7) 6.4 (1.1) 9.7 (2.0) 16.3 (1.0)
CC1/2 1.00 (0.94) 0.99 (0.54) 0.99 (0.87) 1.00 (0.60)
Completeness (%) 99.8 (99.7) 99.9 (100) 98.0 (79.7) 99.2 (98.9)
Multiplicity 4.8 (4.9) 6.3 (6.8) 2.9 (2.1) 3.1 (3.2)
Refinement
Resolution (A˚) 47.79–3.10‡ 45.22–3.40‡ 42.8–1.80 42.07–1.70
No. unique reflections 11128 7545 51379 112934
Rwork/R free 0.26/0.30 0.25/0.27 0.17/0.20 0.16/0.20
No. of atoms
Protein 3553 1732 3992 3968
Ligand/ion 8 29 168 142
Water 7 – 604 693
B-factors
Protein 98.2 119.9 23.5 26.6
Ligand/ion 84.3 78.7 42.1 30.9
Water 43.4 – 40.7 44.9
Root-mean-square (R.m.s.) deviations
Bond lengths (A˚) 0.002 0.001 0.008 0.020
Bond angles (◦) 0.551 0.435 0.98 1.654
Reference model§ 4GYZ 4GYZ N/A N/A
Ramachandran
Outliers (%) 5 2 0 0
Favoured (%) 92.4 92.6 97.9 97.9
MolProbity score 1.8 1.9 1.28 1.50
detailed characterization of specific protein-drug interactions,
clear difference electron density maps identified the binding
site and general pose of this class of inhibitor bound to TDP2
(Supplementary Figure S2).
The experimentally determined binding-mode of 163 is
surprisingly different from that predicted by molecular docking
studies [13], in which the pyrimido-dione ring of the tricyclic core,
was hypothesized to bind to the magnesium cofactor – required
for catalytic activity of TDP2 – and made few (if any) hydrogen
bonds directly to the protein.
Instead, our data indicate that the tricyclic deazaflavin core of
163 unexpectedly packs against an extended hydrophobic patch,
formed by the side chains of Trp297, Thr299, Leu305, Ile307, Cys311,
Leu313 and Phe315, which lies at the mouth of the channel leading to
the active site, more than 9 Å from the catalytic Mg2 + ion bound
by the carboxyl side chains of Asp122 and Glu152 (Figure 2E).
Due to the persistently poor crystallization behaviour of the
human protein, and the need to characterize fully this unusual
and unexpected binding mode of the deazaflavin inhibitor, we
switched species and used the murine form of the enzyme
(mTDP2CAT), which yielded well-behaved crystals diffracting to
high-resolution; as in previous studies [24]. As a preliminary
experiment, we tested the ability of 163 to inhibit mTDP2CAT in
a gel-based assay. Unexpectedly, although 163 readily inhibited
the catalytic activity of hTDP2CAT – preventing conversion of
5′-phosphotyrosyl termini to 5′-phosphates on a DNA duplex
substrate – it failed to inhibit the mouse protein (Figure 2F).
Comparison of the mouse and human TDP2 amino acid
sequences revealed substantial differences in a segment of
polypeptide, denoted the ‘M7-motif’ [24], delimited by highly
conserved ‘TWDT’ (amino acids 296–299 in humans) and
‘RFDR’ (amino acids 314–317) motifs. A multiple amino acid
sequence alignment of this region (Figure 3A) shows it to be
conserved in length (14 residues) among different organisms, but
poorly conserved in amino acid sequence and somewhat variable
in conformation (Figure 3B). Significantly, the M7-motif maps to
the binding site we observe for 163 in hTDP2CAT, where human
TDP2 residues Cys311 and Leu313, along with Ala309, coalesce
to form a ‘hydrophobic-shelf’ on which the deazaflavin core
of 163 sits. Replacement of Cys311 and Leu313 in hTDP2 with
the equivalent residues Tyr321 and His323 in mTDP2 disrupts
this hydrophobic-shelf and explains the resistance of the mouse
enzyme to the deazaflavin-based inhibitors (Figure 3C).
Development of a protein surrogate: m2hTDP2CAT
Although hTDP2CAT is effectively inhibited by 163 and related
deazaflavins, its poor crystallographic behaviour greatly limits
the degree to which structure-led approaches can be used in order
to optimize these compounds further for clinical development.
Conversely, mTDP2CAT, although crystallographically well-
behaved and able to yield high-resolution structures, does not
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Figure 3 The M7-motif of TDP2
(A) Multiple amino acid sequence alignment for the M7-motif of TDP2. This region is flanked by the two highly conserved ‘TWDT’ (coloured orange) and ‘RFDR’ (coloured cyan) motifs. Amino acid
boundaries and UniProt accession codes are as indicated. Partially conserved amino acids are additionally identified by the bold, underlined text. (B) Superposition of the M7-motif taken from X-ray
crystal structures of human (the present study), mouse (PDB:4GYZ), zebrafish (4F1H) and worm TDP2 (4FVA). The spatial arrangement of the ‘TWDT’ and ‘RFDR’ motifs is highly conserved. The loop
connecting these two elements is conserved in length, but varies somewhat in conformation. For clarity, numbering is only shown for the human protein. (C) Molecular cartoon of 163 in complex
with hTDP2CAT highlighting the position of two amino acid residues (Leu313 and Cys311; black text on white background) that are not conserved in the M7-motif of mouse TDP2 (equivalent residues
His323 and Tyr231; white text on grey background), but are essential for compound binding. (D) Top: representative image for the gel-based enzyme activity assay using m2hTDP2CAT. The introduction
of four amino acid changes into mTDP2CAT – to generate m2hTDP2CAT – restores the inhibitory activity of 163. Labelling as per Figure 2(D). Bottom: quantification of gel-based assay. Data represent
the mean of three independent experiments, with errors bars representing one S.D.
bind deazaflavin inhibitors due to sequence differences in the
M7-motif.
To overcome these problems, we designed a series of mutations
in the M7-motif and associated structure, designed to ‘humanize’
the inhibitor-binding site of mTDP2 while retaining the favourable
murine surface that facilitates well-ordered crystals. Rather than
exchange the entire mouse M7-motif for that of the human protein,
we decided as an initial approach only to ‘humanize’ the amino
acids expected to be in the proximity of the bound compound, and
not those which would simply point towards solvent. We therefore
created the expression construct m2hTDP2CAT (m2h=mouse-‘to’-
human) by mutating the following mouse residues to their human
equivalent: E242G, Q278R, Y321C and H323L.
The m2hTDP2CAT protein retained full phosphodiesterase
activity, and consistent with our prediction that the resistance of
the mouse protein to deazaflavins was due to the variant M7-motif,
this activity in m2hTDP2CAT was inhibited by 163 (Figure 3D).
As no further optimization of the ‘humanized’ construct was
therefore required, m2hTDP2CAT was used for all subsequent
structural analyses.
High-resolution co-crystal structure of m2hTDP2CAT bound to 163
We were able to validate our approach, by determining the X-ray
crystal structure of m2hTDPCAT bound to 163, at a resolution of
1.8 Å (Table 1). Superposition of the low-resolution hTDP2CAT
and high-resolution m2hTDP2CAT structures in complex with 163,
confirms that the binding site is conserved across both proteins
(Supplementary Figure S3). However, the higher resolution data
obtained with the m2hTDP2CAT surrogate, allows a far more
detailed characterization of the interaction of the inhibitor with
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Figure 4 Molecular interactions of 163 and 148 with m2hTDP2CAT
(A) Molecular interactions made by 163. (B) Molecular interactions made by 148. (C) The p-hydroxyl of the 148 pendant group makes a series of water-mediated interactions with the side chain of
Asp272 and Asn274, in close proximity to the active site of the enzyme. Molecular cartoons are shown throughout, with selected side chains and compounds shown in stick representation. Amino acids
labelled in bold italic text, represent those that have been mutated from their mouse counterpart, in order to generate m2hTDP2CAT. Please see associated key for details of the colouring scheme.
the TDP2 catalytic domain (Figure 4A and Supplementary Figure
S2).
The guanidinium head group of Arg276 (all numbering is for
the mouse protein, the equivalent in human is calculated by
subtraction of 10) is involved in an extensive hydrogen-bond
network, including both carbonyl and nitrogen groups of the
163 pyrimido-dione ring, as well as the backbone carbonyl and
side chain (via a water molecule) of Asp277. As in the fully
human protein, amino acids of the M7-motif coalesce to form
the ‘hydrophobic-shelf’, which permits extensive van der Waals
interactions with the tricyclic deazaflavin core; these residues
include Trp307, Ile317, Ala319, Cys321 (text in italics represent a
‘humanized’ amino acid residue), Leu323 and Phe325 (Figure 3A).
The tetrazole R1 substituent of 163, is directed towards solvent, but
packs against the carbon-atoms of the Arg241 side chain, providing
additional van der Waals interactions.
High-resolution co-crystal structure of m2hTDP2CAT bound to 148
Raoof et al. [13] also described and characterized two
hydroxyphenyl substituents at the R1 position of the deazaflavin
core, in combination with the cyano group at the R3 position:
compound 147 (3-hydroxyphenol) and 148 (4-hydroxyphenol)
with reported EC50 values of 50 nM and 90 nM respectively
(Figure 2A). We were successful in obtaining diffracting crystals
of 148 in complex with m2hTDP2CAT, determining the structure
at a resolution of 1.7 Å (Table 1). In this instance, we also
supplemented the purification buffers with manganese chloride
(iso-structural with magnesium, but readily discernible in electron
density maps) in order to more fully define any interaction of
the inhibitors with the metal-dependent catalytic centre of the
enzyme.
In the 148 complex, the side chains of Arg276 and Asp277 make
the same set of interactions with the carbonyl and nitrogen groups
of the pyrimido-dione ring, as with 163. However, the side chain
of Arg241 occupies a different position, breaking its hydrogen
bond interaction with Asp277, and instead packing in a π–π
interaction against the face of the tricyclic core of the deazaflavin
(Figure 4B and Supplementary Figure S2). Interestingly, the p-
hydroxyl group of the R1 substituent in 148, points directly
towards the catalytic core of the protein and makes a series
of water-mediated contacts to the side chains of Asp272 and
Asn274. Electron density maps also clearly showed the position
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Figure 5 Deazaflavin binding relative to bound DNA
(A) The deazaflavin-scaffold interacts with the ‘hydrophobic shelf’ formed by residues of the M7-motif. Molecular surface representations for: (left) m2hTDP2CAT in complex with 163; (middle) mouse
TDP2CAT in complex with a double-stranded product DNA (PDB: 4GZ1); (right) zebrafish TDP2CAT in complex with a single-stranded product DNA (PDB: 4F1H). (B) Superposition of structures
reveals that the first two nucleotides of either product DNA (Nuc1, Nuc2) occupy highly similar positions when bound to TDP2. The dezaflavins occupy a position equivalent to Nuc2, with the pendant
group sitting at the position of the 5′-phosphate, and the deazaflavin core at those of the ribose and base moieties. In both panels, the carbons of the previously modified 5′ nucleotide are coloured
yellow, and those of the deazaflavin 163 in green.
of a tartrate molecule (picked up from the crystallization mother
liquor), which is hydrogen-bonded to the side chain of Ser239,
as well as an extensive series of water-mediated interactions
with several amino acid residues surrounding the catalytic centre.
The tartrate molecule also completes the octahedral coordination
of the Mn2 + ion (marking the position of the catalytic Mg2 +
cofactor) (Figure 4C). Moreover, its position marks a potentially
useful ‘molecular interaction path’ that could be utilized in future
iterations of TDP2 inhibitor compounds.
Mode of action of deazaflavin inhibitors of TDP2
Several structures for the catalytic domain of TDP2 in complex
with nucleic acid have been reported [24,25]. However, there is
disagreement between these structures regarding the path that
the bound DNA follows across the protein surface; potentially
as a result of the different substrates used (double compared
with single-stranded) or possibly due to different crystal packing
interactions.
However, taking PDB entries 4GZ1 and 4F1H as representative
examples of the two different modes of TDP2–product DNA
interaction, we note that although the DNA trajectories are
different (Figure 5A), the position of the first (Nuc1) and second
nucleotides (Nuc2) of the previously modified strand are highly
similar in both structures (Figure 5B).
Regardless of which of these TDP2–product DNA structures
actually represents a physiologically relevant binding mode,
comparison with the structures reported here shows that the
deazaflavins occupy a position equivalent to that of Nuc2, with
the pendant group sitting at the position of the 5′-phosphate, and
the deazaflavin core at the position of the ribose and base moieties.
DISCUSSION
The proteins that constitute the DNA damage response (DDR)
are increasingly being recognized as attractive targets for the
development of new drugs, which exploit the inherent genomic
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instability found in many cancers [27,28]. This field has been
galvanized by the approval of olaparib as a monotherapy for the
treatment of specific subsets of patients with advanced ovarian
cancer. Olaparib is an inhibitor of the DNA damage sensor
poly(ADP-ribose) polymerase 1 (PARP1), which exploits cancer-
associated genetic defects in one DNA repair system (homologous
recombination-mediated DSB repair) by inhibiting a second
system (single-strand break repair) to achieve potent and selective
‘synthetic lethality’ against tumour cells [29].
DDR enzymes that utilize cofactors – such as PARPs or protein
kinases for example – fall within the traditional canon of drug
development targets; i.e. where a specific cofactor-competitive
inhibitor can be readily found. However, many biologically
interesting DNA repair ‘targets’ for cancer drug discovery lack
such cofactors and instead act directly on DNA. These present the
challenge of discovering compounds capable of out-competing an
often substantial protein–DNA interaction potentially dominated
by highly polar interactions with the negatively-charged sugar-
phosphate backbone.
The discovery of deazflavins as TDP2 inhibitors [13]
highlighted the possibility that uncharged and ‘drug-like’
competitive inhibitors of DNA binding to a DNA repair enzyme,
could be found and developed. However, the mode of action
of these was unclear, and limited further optimization of these
compounds towards clinical development. The structural analysis
we describe here reveals a very unusual binding mode in which the
deazaflavin core and pendant groups act as nucleoside mimetics,
binding to the hydrophobic ‘shelf’ that can support the exposed
face of the last base-paired nucleotide at the transition from
double-stranded to single-stranded DNA in the mouse TDP2CAT–
product DNA structure (PDB: 4GZ1). Although this deazaflavin
series is specific for TDP2, many enzymes involved in DNA
repair and manipulation engage with a dsDNA–ssDNA transition,
and structural studies of their complexes with DNA reveal the
presence of functionally equivalent ‘shelf’ structures that could
also provide binding sites for DNA-competitive small ligands
[30–32] that could have utility as selective inhibitors of the DNA
repair pathways such enzymes mediate.
Interestingly, TDP2 has previously also been identified as a host
factor required for the replication of picornaviruses in mammalian
cells [5]; encoding the essential ‘unlinkase’, required to cleave a
unique covalent interaction made between the virally-encoded
protein VPg and RNAs produced by the virion. It is therefore
feasible that small molecule inhibitors of TDP2 may also find
utility as novel antiviral agents, for the treatment of picornoviral
infections; which includes rhinovirus and enterovirus pathogens,
both of which produce high morbidity rates in infants and children
[5,33].
It is worth noting here (as previously reported [13]) that
deazaflavin-based compounds are, in themselves, highly unlikely
to be suitable as anticancer agents; in most part due to the general
inability of the chemical scaffold to penetrate the cell membrane
of mammalian cells. However, with the data gleaned from the
high-resolution crystal structures presented here, we now have a
detailed understanding of their mode of action, which will in turn,
inform the discovery and development of alternative scaffolds,
and may eventually lead to the conversion of this highly useful
‘tool compound’ into a potential bona fide drug candidate for the
treatment of disease.
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